Notice of Special Interest to Encourage Eligible NIH HEAL Initiative Awardees to Apply for PA-20-222: Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

The NIH has a strong interest in the diversity of the NIH-funded research enterprise (see NIH notice NOT-OD-20-031) and encourages institutions to diversify their scientific workforce by increasing the participation of individuals from groups identified as underrepresented in the biomedical, clinical, behavioral, and social sciences. Participating institutes continue to support these efforts through ongoing programs and supplement funding opportunities. This specific notice reiterates this interest and encourages eligible grant and cooperative agreement awardees in the HEAL Initiative community to apply for administrative supplements in response to PA-20-222 (or any subsequent reissuances), Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed). This notice is part of the NIH’s Helping to End Addiction Long-term (HEAL) Initiative to speed scientific solutions to the national opioid public health crisis. The NIH HEAL Initiative is a trans-NIH effort to (1) improve prevention and treatment strategies for opioid misuse and addiction and (2) enhance pain management. More information about the HEAL Initiative is available at: https://heal.nih.gov/.

Application and Submission Information

Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalent:

  • PA-20-222 - Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)

PA-20-222 is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. However, applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.

If interested in this opportunity, Duke investigators should contact:

Cinthia E. Sanchez, Ph.D. (cinthia.sanchez@duke.edu), CTSA Program Director, Duke Clinical & Translational Science Institute (CTSI) 

Application Due Date(s) – November 15, 2020, February 15, 2021, May 15, 2021, November 15, 2021, February 15, 2022, May 15, 2022, November 15, 2022, February 15, 2023, May 15, 2023, November 15, 2023, February 15, 2024, and May 15, 2024 

NOT-NS-20-107

Agency Website

Eligibility Requirements

 

        Amount Description

        Application budgets are limited to no more than the amount of the current parent award, and must reflect the actual needs of the proposed project. Direct costs for individual administrative supplements vary from less than $5,000 to more than $100,000 depending on the career level of the candidate. Administrative supplements end with the currently funded competitive cycle of the parent grant. Budget requests may also be limited by the awarding IC.  See Table of IC-Specific Information, Requirements and Staff Contacts for more details.

        The funding mechanism being used to support this program, administrative supplements, can be used to cover cost increases that are associated with achieving certain new research objectives, as long as the research objectives are within the original scope of the peer reviewed and approved project, or the cost increases are for unanticipated expenses within the original scope of the project. Any cost increases need to result from making modifications to the project that would increase or preserve the overall impact of the project consistent with its originally approved objectives and purposes.

        Funding Type

        Grant

        Eligibility

        Faculty

        Category

        Medical
        Medical - Basic Science
        Medical - Clinical Science
        Medical - Translational
        Social Sciences

        External Deadline

        February 15, 2023